(NASDAQ: ARGX) Argenx Se's forecast annual revenue growth rate of 1,457.11% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 102.02%, and it is also forecast to beat the US market's average forecast revenue growth rate of 25.67%.
Argenx Se's revenue in 2025 is $1,917,647.On average, 30 Wall Street analysts forecast ARGX's revenue for 2025 to be $262,386,034,398, with the lowest ARGX revenue forecast at $241,756,474,122, and the highest ARGX revenue forecast at $297,724,837,356. On average, 30 Wall Street analysts forecast ARGX's revenue for 2026 to be $357,782,492,124, with the lowest ARGX revenue forecast at $268,611,523,002, and the highest ARGX revenue forecast at $428,765,269,050.
In 2027, ARGX is forecast to generate $439,263,151,794 in revenue, with the lowest revenue forecast at $337,641,205,464 and the highest revenue forecast at $580,252,158,414.